GLP3, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
The intricate interaction between the HPA axis, neuroinflammation, mitochondrial functioning and oxidative stress might be crucial in mechanisms underlying the beneficial effects of the nutritional interventions in the context of ES
Fifty-eight per cent of people taking or considering taking GLP-1 drugs said weight loss was their main driver, while 42 per cent said diabetes was their primary reason
[DOI] [PMC free article] [PubMed] [Google Scholar] 24.Drmic D, Samara M, Vidovic T, Malekinusic D, Antunovic M, Vrdoljak B, Ruzman J, Milkovic Perisa M, Horvat Pavlov K, Jeyakumar J, Seiwerth S, Sikiric P
Garcia Calvo, M
10.1016/j.foodchem.2024.138739 90 LiuW.CuiX.ZhongY.LiuB.XiaY